Boundless Bio (BOLD) vs Xilio Therapeutics (XLO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Boundless Bio (BOLD) has outperformed Xilio Therapeutics (XLO) over the past year, gaining 105.3% versus a loss of 28.3%. Boundless Bio is the larger company by market cap ($54.8 million vs $53.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BOLD | XLO |
|---|---|---|
| Share price | $2.32 | $7.56 |
| Market cap | $54.78M | $53.40M |
| 1-day change | -2.52% | -1.11% |
| YTD return | +93.33% | -15.63% |
| 1-year return | +105.31% | -28.29% |
| 5-year return | — | -97.29% |
| P/E ratio (TTM) | — | 11.63 |
| EPS (TTM) | $-2.46 | $0.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $43.77M |
| Revenue growth (YoY) | — | +589.88% |
| Net income (latest FY) | $-58.20M | $-35.04M |
| Operating margin | — | -95.92% |
| Net margin | — | -80.05% |
| 52-week high | $3.16 | $10.71 |
| 52-week low | $0.961 | $6.47 |
| Distance from 52-week high | -26.68% | -29.41% |
| Analyst consensus | none | none |
| Avg. price target upside | +72.41% | +164.55% |
| Average volume | 131.34K | 11.54K |
| Shares outstanding | 23.61M | 7.06M |
| Employees | 28 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BOLD has outperformed XLO by 133.6 percentage points over the past year.
About Boundless Bio
BOLD stock →Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Xilio Therapeutics
XLO stock →Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
BOLD vs XLO FAQ
Which is bigger, Boundless Bio or Xilio Therapeutics?
Boundless Bio (BOLD) is larger, with a market capitalization of $54.78M compared with $53.40M for Xilio Therapeutics (XLO).
Which stock has performed better over the past year, BOLD or XLO?
BOLD returned +105.31% over the past 12 months, compared with -28.29% for XLO (price return, excluding dividends). Past performance does not predict future results.
Are Boundless Bio and Xilio Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.